Dinesh V. Patel, PhD

208 posts

Dinesh V. Patel, PhD

Dinesh V. Patel, PhD

@ProtagonistCEO

CEO & President of Protagonist Therapeutics. 38 years of executive, entrepreneural, and scientific experience spanning big pharma & biotechs, and loving it!

Fremont, Sunny California Katılım Şubat 2010
79 Takip Edilen173 Takipçiler
Dinesh V. Patel, PhD retweetledi
Vivek Patel
Vivek Patel@VDP83·
Congrats dad (@ProtagonistCEO)! I'm *so* proud of what you and the @ProtagonistTx team have achieved. 13yrs end-to-end from R&D to full FDA approval for a new drug. It's inspiring.
Dinesh V. Patel, PhD@ProtagonistCEO

Proud moment for Protagonist Therapeutics: today’s FDA approval of ICOTYDE marks 13 years of scientific dedication and operational excellence. A testament to our peptide platform and collaboration with Johnson & Johnson. Grateful to all who made this possible.

English
0
2
7
259
Dinesh V. Patel, PhD
Dinesh V. Patel, PhD@ProtagonistCEO·
Proud moment for Protagonist Therapeutics: today’s FDA approval of ICOTYDE marks 13 years of scientific dedication and operational excellence. A testament to our peptide platform and collaboration with Johnson & Johnson. Grateful to all who made this possible.
Protagonist Therapeutics@ProtagonistTx

Today the FDA approved ICOTYDE™ (icotrokinra), the first targeted oral peptide option for first-line systemic treatment of plaque psoriasis. This milestone reflects the power of our science and platform. Thank you to the PTGX team, Johnson & Johnson, investigators and patients who made it possible. Read more: bit.ly/4sckfLP

English
0
1
8
380
Dinesh V. Patel, PhD
Dinesh V. Patel, PhD@ProtagonistCEO·
The FDA’s decision to grant Priority Review for rusfertide marks an important step in our decade-plus long and ongoing journey. Big Congrats and sincere thanks to the @ProtagonistTx team for your persistence, scientific rigor, and commitment. We are pleased to be working with Takeda on this potential first-in-class therapy for patients with polycythemia vera.
Protagonist Therapeutics@ProtagonistTx

Today, Protagonist and Takeda announced that the U.S. Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) and granted Priority Review for rusfertide, an investigational, first-in-class hepcidin mimetic peptide therapeutic for the treatment of adults with polycythemia vera (PV). Read more details in our latest press release: feeds.issuerdirect.com/news-release.h…

English
1
0
4
209
Dinesh V. Patel, PhD
Dinesh V. Patel, PhD@ProtagonistCEO·
Protagonist is off to a strong start in 2026. Together with Takeda, we’ve submitted an NDA to the FDA for rusfertide, a first-in-class investigational hepcidin mimetic for PV. Grateful to the patients, investigators, and teams who made this possible. Looking forward to JPM and sharing more updates ahead!
Protagonist Therapeutics@ProtagonistTx

Takeda and Protagonist Therapeutics have announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking approval of rusfertide for the treatment of adults with polycythemia vera (PV). Read more in our latest press release: bit.ly/4sqgV03

English
0
0
4
195
Dinesh V. Patel, PhD retweetledi
Protagonist Therapeutics
Protagonist Therapeutics@ProtagonistTx·
Happy holidays from Protagonist Therapeutics! Warmest wishes to you and yours this holiday season ❄️
English
0
2
5
140
Dinesh V. Patel, PhD retweetledi
Protagonist Therapeutics
Protagonist Therapeutics@ProtagonistTx·
It’s #WorldPsoriasisDay, and this year's theme aims to put a spotlight on Psoriatic Disease and Comorbidities. Psoriasis is a journey of visible and invisible challenges that not only impacts the skin, but also overall health and well-being. At Protagonist Therapeutics, we’re proud to join @NPF and the global psoriasis community to raise awareness, advance research, and work toward a future with better care for the 125 million people around the globe living with psoriasis.
English
0
1
4
212
Dinesh V. Patel, PhD retweetledi
Protagonist Therapeutics
Protagonist Therapeutics@ProtagonistTx·
For more than 20 years, @CALifesciences has celebrated individuals and organizations who are making exceptional contributions to the life sciences industry. There is one more day for the Pantheon 2025 Awards voting, and our Protagonist team needs your help to win! Vote for us in the Biopharma Product of the year category today: share.hsforms.com/1FMf9fZg4QOuWC…
Protagonist Therapeutics tweet media
English
3
1
5
188
Dinesh V. Patel, PhD
Dinesh V. Patel, PhD@ProtagonistCEO·
We are honored and happy with such a nomination, which in itself is a great recognition. Congrats to team @ProtagonistTx and to all the well deserving nominees.
Protagonist Therapeutics@ProtagonistTx

We are pleased to see Protagonist be named a @Citeline 2025 #ScripAwards finalist for “Clinical Advance of the Year” in recognition of the highly positive outcome of the Phase III VERIFY study of rusfertide in polycythemia vera (PV). We are honored to be in the company of other innovative finalists working to advance healthcare. See the shortlist here: citeline.com/en/awards/scri…

English
0
1
5
99
Dinesh V. Patel, PhD
Dinesh V. Patel, PhD@ProtagonistCEO·
We’re pleased to see new data at #EADV2025, from icotrokinra’s Phase 3 durability and head-to-head superiority vs. Sotyktu to PN-881’s potent dual IL-17A&F inhibition and preclinical efficacy. These results once again reflect the strength of our oral peptide platform.
Protagonist Therapeutics@ProtagonistTx

From platform to pipeline to patients. Presentations this week at #EADV2025 will demonstrate the potential of our peptide therapeutic discovery and development platform to redefine standards in psoriasis care. Read more: feeds.issuerdirect.com/news-release.h…

English
1
1
6
461
Dinesh V. Patel, PhD
Dinesh V. Patel, PhD@ProtagonistCEO·
The EMA filing for #icotrokinra marks another major step forward toward bringing this first-in-class investigational therapy with the convenience of a once-daily tablet to patients with psoriasis. We at Protagonist are proud of what our partnership with @JNJNews represents for the future of peptide therapeutics.
Protagonist Therapeutics@ProtagonistTx

Today, we announced that Johnson & Johnson (@JNJNews) has submitted a Marketing Authorization Application to the European Medicines Agency for icotrokinra, a first‑in‑class investigational oral peptide co-discovered by Protagonist and J&J scientists for adults and adolescents with moderate‑to‑severe plaque #psoriasis. Read more: accessnewswire.com/newsroom/en/he…

English
0
1
7
178
Dinesh V. Patel, PhD
Dinesh V. Patel, PhD@ProtagonistCEO·
A landmark moment for #PTGX: the NDA for oral #icotrokinra has been submitted to the FDA. This is the first NDA resulting from our peptide discovery & development platform in collab with our partners at @JNJNews. Congrats & thanks to everyone on the PTGX and J&J teams. Cheers!
Protagonist Therapeutics@ProtagonistTx

News: Protagonist is pleased to announce the submission of a New Drug Application for icotrokinra, the first- and best-in-class oral IL-23R blocker for plaque #psoriasis. Four pivotal Phase 3 ICONIC studies back its potential to transform care and expand across IL-23–mediated diseases. Read more: bit.ly/4nQ8YyW

English
0
1
8
284
Dinesh V. Patel, PhD
Dinesh V. Patel, PhD@ProtagonistCEO·
Back to basics with solid ‘oral peptide’ differentiation in obesity, and with two NDA filings sometime in 2025 in rear view mirror - Icotrokinra with @JNJ and Rusfertide with @TakedaOncology. Feels like a rejuvenating reincarnation!
Protagonist Therapeutics@ProtagonistTx

Today, we hosted a conference call and webcast on our oral obesity development candidate, PN-477. IND-enabling studies are underway, with Phase I study initiation expected in the second quarter of 2026. Read more: bit.ly/4kl5bXj Watch the webcast replay: bit.ly/44nDwiG

English
1
1
8
314

Keşfet

@ProtagonistTx @NPF @CALifesciences @JNJNews @JNJ @TakedaOncology @WSJ @takeda